Imagine a future where wisdom teeth are no longer a source of dread and discomfort. This vision is becoming a reality thanks to TriAgenics and its revolutionary Zero3 Tooth Bud Ablation (TBA) technology.
Every year, millions of Americans endure the painful and expensive process of wisdom teeth removal. While often considered a rite of passage, this procedure carries a significant financial and physical toll. In the U.S. alone, over 10 million wisdom teeth are extracted annually, placing a heavy burden on both individuals and the healthcare system.
TriAgenics’ Zero3 TBA technology aims to eliminate the need for wisdom teeth extraction altogether, offering a proactive approach to dental care. Instead of removing developed wisdom teeth, Zero3 TBA targets the tooth buds in children aged 6 to 12, preventing them from developing into full-grown wisdom teeth.
The procedure is minimally invasive, taking just 60 to 90 seconds per tooth bud and can be completed in about 30 minutes for all four tooth buds. This makes it significantly less disruptive than traditional extraction, and it can be performed by general dentists rather than requiring an oral surgeon, increasing accessibility and potentially reducing costs.
The potential benefits of Zero3 TBA are profound. It could save future generations from the pain, risk, and financial burden associated with wisdom teeth extraction, shifting the focus from reactive treatment to proactive prevention. This approach could fundamentally change how we think about dental health and the management of wisdom teeth.
When comparing Zero3 TBA to traditional methods like prophylactic extraction (removing wisdom teeth before they cause problems) or the monitor-and-treat approach (monitoring teeth and treating issues as they arise), Zero3 TBA emerges as the most cost-effective and least risky option.
TriAgenics is poised to revolutionize the dental industry with its Zero3 TBA technology. The company boasts a 100% success rate in animal trials and a robust intellectual property portfolio. With over $11.5 million in capital raised, TriAgenics is currently preparing for FDA 510(k) clearance and human clinical trials, aiming to bring Zero3 TBA to market in 2025.
The potential market for Zero3 TBA is vast, exceeding $2.5 billion annually, reflecting a strong demand for a less invasive and more cost-effective solution for wisdom teeth management. With interest from oral surgeons and pediatric specialists, Zero3 TBA has the potential to be a game-changer in the dental field.
